In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist Behnam Nabet and his collaborators describe how they used targeted protein degradation in mice to rapidly destroy lung and pancreas tumors caused by a variant of a commonly mutated, cancer-driving gene.
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
An abstract is unavailable.
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
